Advertisement


Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial

2018 ASTRO Annual Meeting

Advertisement

Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).



Related Videos

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation an...

Lung Cancer
Immunotherapy

David Raben, MD, on NSCLC: Results From the PACIFIC Trial

David Raben, MD, of the University of Colorado, discusses overall survival with durvalumab vs placebo after chemoradiotherapy in stage III non–small cell lung cancer (Abstract LBA1...

Prostate Cancer

Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment...

Prostate Cancer

Alan Pollack, MD, on Prostate Cancer: Results From the SPPORT Trial

Alan Pollack, MD, of the University of Miami, discusses study findings on short-term androgen-deprivation therapy with or without pelvic lymph node treatment added to prostate bed–...

Head and Neck Cancer

Bhisham Chera, MD, on Oropharyngeal Cancer: Expert Perspective on Surveillance

Bhisham Chera, MD, of the University of North Carolina, discusses using human papillomavirus found in plasma circulating tumor DNA to monitor cancer recurrence in HPV-associa...

Advertisement

Advertisement



Advertisement